glp-1 news november 2025 As Drugs Go Mainstream, This Expert Says Health is More than a Number on a Scale GLP-1 Agonists Market Report 2025-2033,

And Eli Lilly and Companys new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials

These include: Pre-existing constipation or slow transit constipation Inadequate dietary fibre intake Insufficient fluid consumption Reduced physical activity levels Concurrent medications with constipating effects (such as opioids, certain antidepressants, or iron supplements) Older age , where baseline colonic motility may already be reduced The severity of constipation often correlates with the dose of medication and may be more pronounced during dose escalation phases

The resulting 39-amino acid peptide includes a C20 fatty diacid moiety attached via a linker to a lysine residue, which enables albumin binding and extends the medication's half-life to approximately five days

doi: 10.1007/s00125-017-4347-7

[68] demonstrated the hypocholesterolemic effects of yerba mat in healthy subjects with normo- or dyslipidemia

This is pressuring manufacturers to refine marketing language, substantiation practices, and product-positioning strategies across digital wellness channels